Physician profile
Phillip E Reilly
NPI 1689635682
$2,606.09
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,025 · 2020: $566 · 2021: $14.33.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $518.78 | 2019-2021 | |
| Pfizer INC. | $353.81 | 2019-2020 | |
| Amgen INC. | $328.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $323.16 | 2019 | |
| Lilly USA, LLC | $216.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $210.48 | 2019-2020 | |
| Allergan, INC. | $168.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $74.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.35 | 2019-2020 | |
| Amarin Pharma, INC. | $57.66 | 2019 | |
| Intuitive Surgical, INC. | $33.27 | 2019 | |
| Vifor Pharma, INC. | $30.93 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $29.71 | 2019 | |
| Sunovion Pharmaceuticals INC. | $28.71 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $25.13 | 2019-2020 | |
| Pbg Puerto Rico LLC | $24.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.90 | 2019 | |
| Seqirus USA INC | $18.35 | 2019 | |
| Sanofi-Aventis U.S. LLC | $10.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Reilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.